Tagged with GI

China A roundup of some of the biggest recent stories coming out of China, including the commerce minister’s peace offering to international drug companies; CSPC Pharmaceutical Group’s partnership with Pfizer; Merck’s EUR 70 million manufacturing investment; the licensing agreement between Zhejiang Doer Biologics and BioNTech, and Moderna’s deal to develop and…

Belgium Univercells is a group of companies founded a decade ago based around the concept of revolutionizing the availability of biologics around the world through making essential medicines affordable to all, in both quality and price. CEO Hugues Bultot outlines the scale and scope of the organisation today, its fundraising and…

GSK GSK has undergone a number of changes in recent years. After driving a major transformation that began in 2017 to strengthen its R&D performance, the British multinational suffered the impact of COVID-19, spun off its consumer healthcare arm and returned to revenue growth. GSK country managers PharmaBoardroom has interviewed over…

Europe The European Federation of Pharmaceutical Industries and Associations (EFPIA) has elected a new president and vice presidents who have set out a key priority for their term: a series of amendments to the proposed European Commission (EC) pharmaceutical legislation reform, which the organisation has warned will further accelerate the loss…

Global Global biopharma is increasingly moving towards biologic medicines, which promise a greater impact on patient’s lives than the small-molecule drugs that preceded them, but which come with significant added costs and complexity. Against this backdrop, biologic drug developers are leaning evermore on experienced contract development and manufacturing organizations (CDMOs), of…

Belgium Vanja Hoeben oversees the Benelux cluster for South Africa-headquartered specialty and branded pharma firm Aspen. He describes the reorganisation that his organisation has undergone in the past few years, some of the key trends at play in the Belgian generics market, and his hopes for how a more sustainable healthcare…

Belgium Maria Fernanda Prado highlights some of the lessons drawn from her extensive experience in emerging markets which remain applicable in her current role as Janssen’s managing director for the Benelux region. Belgium, the home country of Dr Paul Janssen, continues to be a significant part of the company’s global operations,…

Takeda Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC and consumer goods. Here, four country and regional managers that PharmaBoardroom has spoken to in the past 12 months discuss…

Belgium Werner De Prins oversees Bayer’s operations in Benelux, a significant region for the global group with over 2000 employees, a turnover of around EUR 1.2 billion and 10 different sites across pharmaceuticals, crop science and consumer health, covering marketing & sales, R&D, and production with a global reach. De Prins…

Belgium Stefan Joris of the Belgian Cystic Fibrosis Association (BCFA) highlights the progress that has been made on cystic fibrosis screening of newborns and reimbursement of innovative modulator therapies in Belgium in the past few years. Joris also explains why the move to better integrate the patient voice into the country’s…

Belgium Dr Frank Nobels, one of Belgium’s leading endocrinologists and diabetologists, introduces the Belgian Diabetes Forum – a multi-stakeholder initiative which aims to create efficient policy engagement in diabetes and make better prevention of diabetes, better care and a higher level of well-being for people with diabetes a reality. Dr Nobels…

Belgium With two in-house Clinical Research Units (PCRUs), Pfizer uniquely keeps its phase I research within the company. As Medical/Scientific advisor at the Brussels PCRU and with a history of more than 20 years there, Dr Isabelle Huyghe shares the workings of the PCRU, explains how study participants are recruited, and…